GoKawiilStudy ties tRNA gene dosage to prostate cancer lineage shifts and drug resistance
Researchers at the Fred Hutchinson Cancer Center analyzed metastatic prostate cancer samples and cell line models, including treatment-resistant variants, to study how transfer RNA (tRNA) abundance influences tumor behavior. The work examined patient tumor samples collected via rapid autopsy alongside multiple prostate cancer cell lines adapted to mimic lineage plasticity and resistance to androgen-deprivation therapy.
GoKawiil's interpretation of the reporting above, not reported fact.
The findings suggest that tRNA dosage, a layer of gene regulation beyond DNA mutations, could help explain why prostate tumors switch lineage identity and evade hormone-based treatments. This points to a potential new axis for understanding and possibly targeting treatment resistance, though translating such mechanistic insight into therapies would require further validation.
- Study used patient metastatic prostate cancer samples collected via rapid autopsy under IRB approval
- Multiple prostate cancer cell lines, including resistant variants like LNCaP-abl, were used to model lineage plasticity
- Findings link tRNA gene dosage to cancer lineage dependency and resistance mechanisms
Source: nature.com — Kim, 2026-10-07
Published there as: “tRNA dosage regulates lineage dependency and resistance in prostate cancer”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.